1. Purinergic Signalling: Therapeutic Developments
   Geoffrey Burnstock, 2017, Front. Pharmacol. CrossRef
2. Inhibitors of connexin and pannexin channels as potential therapeutics
   Joost Willebrords et al, 2017, Pharmacology & Therapeutics CrossRef
3. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression
   Geoffrey Burnstock et al, 2017, Purinergic Signalling CrossRef
4. Modulation of the main porcine enteric neuropeptides by a single low-dose of lipopolysaccharide (LPS) Salmonella Enteritidis
   Anita Mikołajczyk et al, 2017, Gut Pathog CrossRef
5. The scavenger activity of the human P2X7 receptor differs from P2X7 pore function by insensitivity to antagonists, genetic variation and sodium concentration: Relevance to inflammatory brain diseases
   Amber Ou et al, 2018, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
6. The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
   Luiz E. B. Savio et al, 2018, Front. Pharmacol. CrossRef
7. The therapeutic potential of purinergic signalling
   Geoffrey Burnstock, 2018, Biochemical Pharmacology CrossRef
8. Identification of glia phenotype modulators based on select glial function regulatory signaling pathways
   Sun-Hwa Lee et al, 2018, Expert Opinion on Drug Discovery CrossRef
9. P2X7 as a scavenger receptor for innate phagocytosis in the brain
   Ben J Gu et al, 2018, British Journal of Pharmacology CrossRef
10. The role of convergent ion channel pathways in microglial phenotypes: a systematic review of the implications for neurological and psychiatric disorders
    Laiana A. Quagliato et al, 2018, Transl Psychiatry CrossRef
11. P38 mitogen-activated protein kinase and Parkinson’s disease
    Jianying He et al, 2018 CrossRef
12. Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment
    Giorgia Scarpellino et al, 2019, PRA CrossRef
13. Brilliant blue G protects against brain and liver tissue damage during systemic endotoxemia in rats treated with lipopolysaccharide
    Omar M. E. Abdel-Salam et al, 2019, Comp Clin Pathol CrossRef
14. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers
    Donatienne Van Weehaeghe et al, 2019, Eur J Nucl Med Mol Imaging CrossRef
15. null
    Laura de Diego-García et al, 2020 CrossRef
16. P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/ Neuroregenerative Effects in an Animal Model of Parkinson’s Disease
    Ágatha Oliveira-Giacomelli et al, 2019, Front. Cell. Neurosci. CrossRef
17. null
    Roberta Andrejew et al, 2019 CrossRef
18. The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson’s disease model
    Nida Jamali-Raeufy et al, 2020, Metab Brain Dis CrossRef
19. Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS
    Peter Illes et al, 2020, Cells CrossRef
20. P2X7 Receptor is Involved in Mitochondrial Dysfunction Induced by Extracellular Alpha Synuclein in Neuroblastoma SH-SY5Y Cells.
    Anna Wilkaniec et al, 2020, Int J Mol Sci CrossRef
21. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
    Francesco Calzaferri et al, 2020, Med Res Rev CrossRef
22. ATP Signaling Controlling Dyskinesia Through P2X7 Receptors
    Analu A. Fonteles et al, 2020, Front. Mol. Neurosci. CrossRef
23. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases
    Peter Illes, 2020, IJMS CrossRef
24. Implication of Neuronal Versus Microglial P2X4 Receptors in Central Nervous System Disorders
    Alexia Duveau et al, 2020, Neurosci. Bull. CrossRef
25. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets
    Jeffrey H Meyer et al, 2020, The Lancet Psychiatry CrossRef
26. In Vitro Chemopreventive Potential of Phlorotannins-Rich Extract from Brown Algae by Inhibition of Benzo[a]pyrene-Induced P2X7 Activation and Toxic Effects
    Mélody Dutot et al, 2021, Marine Drugs CrossRef
27. The role of P2X7R in neuroinflammation and implications in Alzheimer's disease
    Yi-He Chen et al, 2021, Life Sciences CrossRef
28. Crosstalk Between ATP-P2X7 and Adenosine A2A Receptors Controlling Neuroinflammation in Rats Subject to Repeated Restraint Stress
    Liliana Dias et al, 2021, Front. Cell. Neurosci. CrossRef
29. Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and estrogen receptors’ modulation
    Esther T. Menze et al, 2021, International Immunopharmacology CrossRef
30. P2X7 Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches
    Paul R. Territo et al, 2021, Front. Cell. Neurosci. CrossRef
31. P2X7 receptor/NLRP3 inflammasome complex and α‐synuclein in peripheral blood mononuclear cells: a prospective study in neo‐diagnosed, treatment‐naïve Parkinson’s disease
    Anna Solini et al, 2021, Eur J Neurol CrossRef
32. Atypical Retinal Hemorrhages after Vitrectomy for Idiopathic Macular Hole: Possible Toxicity of Brilliant Blue G
    Jae Jung Lee et al, 2021, Korean J Ophthalmol CrossRef
33. Inhibition of P2X7 Purinergic Receptor Ameliorates Fibromyalgia Syndrome by Suppressing NLRP3 Pathway
    Ramona D’Amico et al, 2021, IJMS CrossRef
34. P2X Receptor-Dependent Modulation of Mast Cell and Glial Cell Activities in Neuroinflammation
    Barbora Salcman et al, 2021, Cells CrossRef
35. The Tyrosine Phosphatase hPTPRβ Controls the Early Signals and Dopaminergic Cells Viability via the P2X7 Receptor
    Francisco Llavero Bernal et al, 2021, IJMS CrossRef
36. Inherent P2X7 Receptors Regulate Macrophage Functions during Inflammatory Diseases
    Wenjing Ren et al, 2021, IJMS CrossRef
37. Immune Response Studies Based on P2X7 Receptors: A Mini-Review
    Ying Deng et al, 2022, CPD CrossRef
38. null
    Shalini Sharma et al, 2023 CrossRef
39. A Review of Neuroreceptors for Clinical and Experimental Neuropharmacology in Central Nervous System Disorders
    Susan C. McKarns, 2023, CRCEP CrossRef
40. Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
    Jifei Miao et al, 2023, Front. Aging Neurosci. CrossRef
41. Role of the P2 × 7 receptor in neurodegenerative diseases and its pharmacological properties
    Ziyan Hu et al, 2023, Cell Biosci CrossRef
42. Modulation of Microglial Function by ATP-Gated P2X7 Receptors: Studies in Rat, Mice and Human
    Manju Tewari et al, 2024, Cells CrossRef
43. Lacking P2X7-receptors protects substantia nigra dopaminergic neurons and hippocampal-related cognitive performance from the deleterious effects of high-fat diet exposure in adult male mice
    Chiara Rossi et al, 2024, Front. Nutr. CrossRef
44. Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases
    Huiyong Zheng et al, 2024, Front. Immunol. CrossRef
45. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists
    Simran Soni et al, 2024, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef